Section Arrow
ANAB.NASDAQ
- AnaptysBio
Quotes are at least 15-min delayed:2025/07/17 07:43 EDT
Pre Market
Last
 27.29
+0.43 (+1.60%)
Bid
25.1
Ask
29.5
High 28.99 
Low 26.01 
Volume 17 
Regular Hours
Last
 26.86
+0.23 (+0.86%)
Day High 
27.4 
Prev. Close
26.63 
1-M High
27.22 
Volume 
576.64K 
Bid
25.1
Ask
29.5
Day Low
26.3644 
Open
26.81 
1-M Low
21.87 
Market Cap 
782.40M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 24.96 
20-SMA 24.07 
50-SMA 22.42 
52-W High 41.3083 
52-W Low 12.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.76/-4.85
Enterprise Value
796.51M
Balance Sheet
Book Value Per Share
1.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
91.28M
Operating Revenue Per Share
0.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
APMAptorum Group Limited1.94+0.9702+100.04%2.77PE
Pre Market 1.789 -0.151 -7.78%
TNFATNF Pharmaceuticals Inc.0.109+0.0028+2.64%-- 
Pre Market 0.1018 -0.0072 -6.61%
NCNANuCana plc0.0502--0.000%-- 
Pre Market 0.0485 -0.0017 -3.39%
BRNSBarinthus Biotherapeutics plc1.42+0.4+39.22%-- 
Pre Market 1.36 -0.06 -4.23%
WINTWindtree Therapeutics Inc.0.9+0.0714+8.62%0.84PE
Pre Market 1.27 +0.37 +41.11%
Quotes are at least 15-min delayed:2025/07/17 07:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) anda Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.